ReviewFrontiers in immunology2026
Innate immune cells in tumor immunity: dual roles, mechanistic insights, and therapeutic opportunities.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The tumor microenvironment (TME) is a complex ecosystem that dynamically regulates tumor progression and therapeutic responses. Within this environment, innate immune cells play prominent dual roles, acting as both critical mediators of anti-tumor surveillance and facilitators of tumor immune escape. This review comprehensively synthesizes the phenotypic plasticity and functional heterogeneity of key innate immune cell subsets in tumor immunity, including tumor-associated macrophages (TAMs), natural killer (NK) cells, tumor-associated neutrophils (TANs), dendritic cells (DCs), as well as emerging players such as γδ T cells and innate lymphoid cells (ILCs). Mechanistically, we dissect core pathways governing innate immune cell function in the TME: the cGAS-STING pathway regulates type I interferon responses and immunogenicity; the NF-κB/STAT3 network coordinates inflammation and immunosuppression; the PD-1/PD-L1 axis mediates T cell exhaustion and innate cell dysfunction. Additionally, tumor-driven metabolic reprogramming and extracellular vesicles (EVs) intercellular communication collectively shape the immunosuppressive TME. We further evaluate emerging therapeutic strategies targeting innate immunity. This narrative review provides a comprehensive mechanistic framework and theoretical basis for developing precise, innate immunity-targeted cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.